BNP Paribas Asset Management
VKTX icon

BNP Paribas Asset Management’s Viking Therapeutics VKTX Stock Holding History

BNP Paribas Asset Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$63.9K Sell
1,639
-266
-14% -$8.59K ﹤0.01% 1679
2026
Q1 		$62K Sell
1,905
-53,552
-97% -$1.72M ﹤0.01% 1680
2025
Q4 		$1.95M Buy
+55,457
New +$1.96M ﹤0.01% 1069
2025
Q3 		– Sell
-1,002
Closed -$27K – 2079
2025
Q2 		$27K Buy
+1,002
New +$26.4K ﹤0.01% 1391

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

BNP Paribas Asset Management's VKTX Position: Q2 2026 in Review

BNP Paribas Asset Management reduced its Viking Therapeutics (VKTX) stake by 14% in Q2 2026, selling an estimated $8.59K and leaving 1,639 shares worth $63.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1679.

BNP Paribas Asset Management first reported a position in VKTX in Q2 2025 and has held it in 4 quarters since. The position peaked at $1.95M in Q4 2025. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • BNP Paribas Asset Management held 1,639 shares of Viking Therapeutics worth $63.9K as of Q2 2026.
  • BNP Paribas Asset Management sold 266 Viking Therapeutics shares in Q2 2026, an estimated $8.59K.
  • Viking Therapeutics made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q2 2026, its #1679 holding.
  • BNP Paribas Asset Management first reported a position in Viking Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • BNP Paribas Asset Management's Viking Therapeutics position peaked at $1.95M in Q4 2025.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.